PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1464692
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1464692
Viral Vector and Plasmid DNA Manufacturing Market size was valued at USD 5,673.98 Million in 2023, expanding at a CAGR of 19.61% from 2024 to 2032.
The Viral Vector and Plasmid DNA Manufacturing sector represents a vital segment within the biopharmaceutical industry, dedicated to producing viral vectors and plasmid DNA for gene therapy and vaccine development purposes. Viral vectors are genetically engineered viruses used to transport therapeutic genes into target cells, while plasmid DNA serves as a critical component in gene therapy and DNA vaccine production. This market significantly contributes to advancing medical treatments by facilitating the development of innovative therapies for a broad spectrum of genetic disorders, infectious diseases, and cancers. Given the rapid progress in biotechnology and the increasing investment in gene therapy research, the demand for viral vectors and plasmid DNA manufacturing continues to steadily rise. This growth is fueled by factors such as the increasing prevalence of genetic diseases, the expanding pipeline of gene therapy candidates, and the growing adoption of personalized medicine approaches.
Viral Vector and Plasmid DNA Manufacturing Market- Market Dynamics
Advancements in gene therapy to propel market demand
The primary drivers of the market include advancements in gene therapy, as the development of new gene therapies heavily relies on high-quality viral vectors and plasmid DNA. Moreover, enhancements in manufacturing processes have enabled more efficient production of viral vectors and plasmid DNA at larger scales, leading to cost reductions and improved overall quality. With increased investments in the cell and gene therapy research space, there is significant demand for viral vectors in the market. Consequently, various organizations are providing funds to accelerate developments in manufacturing processes for viral vectors. For instance, in September 2019, Next Generation Manufacturing Canada granted USD 1.89 million to a consortium led by iVexSol Canada for the development of an advanced manufacturing process for lentiviral vectors. iVexSol Canada, a vector manufacturing company, has collaborated with several entities to develop an advanced LVV manufacturing platform.
Viral Vector and Plasmid DNA Manufacturing Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.81% over the forecast period (2024-2032)
Based on Vector Type segmentation, adeno-associated virus was predicted to show maximum market share in the year 2023
Based on Workflow segmentation, downstream processing was the leading type in 2023
Based on Disease segmentation, Cancer was the leading type in 2023
Based on end user segmentation, research institute was the leading type in 2023
Based on Application segmentation, Antisense & RNAi Therapy was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Viral Vector and Plasmid DNA Manufacturing Market is segmented on the basis of Vector Type, Workflow, Disease, Application, End User and Region.
The market is divided into six categories based on vector type: Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids and Others. In terms of vector type, the adeno-associated virus (AAV) segment led the market with the largest revenue share in 2023. AAVs are in high demand, with their utilization in clinical trials increasing rapidly due to their precision in delivering genes to the region of interest. This rising adoption is attributed to clinical trials related to the development of orthopedic and ocular gene therapies demonstrating increased efficiency and efficacy. An article published in Springer in August 2022 stated that AAV-mediated gene therapy could prevent acquired hearing loss, further highlighting the expanding applications of AAV across various therapeutic areas.
The market is divided into two categories based on Workflow: Upstream Manufacturing and Downstream Manufacturing. Based on the workflow, the downstream processing segment dominated the market in 2023 with the largest revenue share, owing to highly complex procedures involved in polishing and purifying clinical-grade final products. With the growing demand for clinical-grade viral vectors, manufacturers are actively engaged in developing novel, cost-effective downstream processes to address challenges associated with conventional lab-scale vector manufacturing. This approach is expected to support market growth, as seen in examples such as combining fed-batch fermentation techniques and genetically optimized cell systems with conventional and novel purification technologies.
Viral Vector and Plasmid DNA Manufacturing Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
In the dynamic landscape of the Viral Vector and Plasmid DNA Manufacturing market, companies implement diverse strategies to uphold competitiveness and address the evolving demands of the biopharmaceutical industry. Collaboration and strategic partnerships play a crucial role in driving innovation, expanding capabilities, and accessing complementary expertise and resources. Companies frequently establish strategic alliances with biopharmaceutical firms, academic institutions, and contract development and manufacturing organizations (CDMOs) to co-develop gene therapy products, exchange research insights, and utilize manufacturing infrastructure. Moreover, investments in research and development (R&D) are essential for advancing manufacturing technologies, enhancing process efficiency, and improving product quality and scalability. Continuous innovation in upstream and downstream processing techniques, purification methods, and analytical technologies is vital for optimizing viral vector and plasmid DNA production processes. Additionally, ensuring regulatory compliance and adhering to Good Manufacturing Practices (GMP) standards are imperative for maintaining product quality, safety, and efficacy throughout the manufacturing lifecycle.
In October 2023, AGC Biologics revealed plans for the expansion of their plasmid DNA (pDNA) manufacturing facility located in Germany. This strategic move is anticipated to enable the company to decrease manufacturing time.
GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Merck KGaA
Lonza
FUJIFILM Diosynth Biotechnologies
Thermo Fisher Scientific
Cobra Biologics
Catalent Inc.
Wuxi Biologics
Takara Bio Inc.
Waisman Biomanufacturing
Genezen laboratories
Batavia Biosciences
Miltenyi Biotec GmbH
SIRION Biotech GmbH
Virovek Incorporation
Others